RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

Core Viewpoint - RenovoRx has appointed Mark Voll as Chief Financial Officer to enhance its leadership team and support the commercialization of its RenovoCath drug-delivery device, marking a significant transition from a clinical stage to a commercial company [1][4]. Group 1: Appointment and Leadership - Mark Voll brings over 30 years of financial leadership experience, having successfully guided high-growth public companies through commercial development [2]. - Voll's role will focus on stockholder communications, budgeting, strategic planning, and finance, which are crucial as RenovoRx commercializes RenovoCath and advances its Phase III TIGeR-PaC clinical trial [3][4]. - CEO Shaun Bagai expressed confidence in Voll's ability to drive sustained commercial execution during this pivotal time for the company [4]. Group 2: Company Overview and Product Information - RenovoRx is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared drug-delivery device designed for targeted therapeutic delivery [7]. - RenovoCath is intended for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications including arteriography and chemotherapeutic drug infusion [6]. - The company has begun commercializing the TAMP therapy platform and RenovoCath, generating approximately $900,000 in revenue from sales in the first nine months of 2025 [8]. Group 3: Clinical Trials and Future Prospects - RenovoRx is evaluating a novel drug-device combination candidate, IAG, in the ongoing Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [9][10]. - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, providing seven years of market exclusivity upon FDA approval [10].